Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Savolitinib Plus Cetuximab and FOLFOX Chemotherapy Versus Cetuximab and FOLFOX Chemotherapy as First-line Treatment for RAS/BRAF Wild-type Metastatic Colorectal Cancer: a Prospective, Randomized, Controlled, Multicenter, Open-label Study

NCT07683403 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07683403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07683403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Savolitinib Plus Cetuximab and FOLFOX Chemotherapy Versus Cetuximab and FOLFOX Chemotherapy as First-line Treatment for RAS/BRAF Wild-type Metastatic Colorectal Cancer: a Prospective, Randomized, Controlled, Multicenter, Open-label Study
Lead sponsor
Fudan University
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
June 30, 2029
Enrollment
138 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (crc)